Cancer Misdiagnosis: Can You Claim for a Missed or Delayed Diagnosis?

You can bring a clinical negligence claim for a missed or delayed cancer diagnosis where a healthcare professional failed to investigate, refer, or act on symptoms that should have prompted urgent assessment, and where that failure allowed the cancer to progress to a stage at which it caused harm that earlier detection would have avoided. The strength of any claim depends on the specific symptoms presented, what the applicable clinical standards required in response, and what difference earlier diagnosis would have made to the treatment needed and the outcome achieved.

Why Does Timing Matter So Much in Cancer Claims?

Cancer is a disease in which the stage at diagnosis is one of the most significant factors in the treatment options available and the likelihood of a successful outcome. The earlier a cancer is detected, the greater the prospect of curative treatment and the less extensive the surgery or other treatment that is typically required. A delay that allows a cancer to progress from stage one to stage three or four is not merely a matter of timing: it can be the difference between a straightforward surgical resection and radical chemotherapy, between cure and palliation, between many years of disease-free survival and a significantly shortened life.

This is why cancer misdiagnosis claims, when they are well founded, are among the most significant in the whole of clinical negligence law. The harm caused by a delayed diagnosis is real, measurable, and in many cases permanent.

What Does a Successful Claim Require?

A cancer misdiagnosis claim requires the claimant to establish three things: that the clinician responsible for their care owed them a duty of care, that the care fell below the required standard, and that the failure caused them harm they would not otherwise have suffered.

Breach of duty: did the clinician meet the required standard?

The primary national standard governing the recognition and referral of suspected cancer in primary care is NICE guideline NG12, Suspected Cancer: Recognition and Referral, most recently updated in January 2026. NG12 covers more than twenty cancer types and sets out the symptoms that should trigger an urgent suspected cancer referral or investigation. Its recommendations are based on a threshold of a 3 per cent positive predictive value: any symptom or combination of symptoms carrying at least a 3 per cent risk of cancer in the relevant population warrants a clinical response.

A GP who sees a patient presenting with symptoms meeting the NG12 threshold and does not refer is departing from the national standard. A departure without documented clinical justification is very difficult to defend.

The Bolam test, established in Bolam v Friern Hospital Management Committee [1957] 1 WLR 582, provides that a clinician is not negligent if their conduct accords with a practice accepted as proper by a responsible body of medical opinion. However, the House of Lords confirmed in Bolitho v City and Hackney Health Authority [1998] AC 232 that any such body of opinion must be capable of withstanding logical analysis. A failure to follow NG12 in the face of a clear presenting picture will rarely survive that scrutiny.

Failures in the diagnostic pathway can also arise further along the chain: a radiologist who misreads a scan, a pathologist who misclassifies a malignant biopsy as benign, a specialist who fails to follow up an abnormal investigation result. Each of these can form the basis of a claim independently of the primary care failure.

Causation: did the delay make a difference?

This is the most legally complex element of any cancer delay claim, and it is where the distinction between a claim that succeeds and one that does not is often decided.

The House of Lords addressed the causation question directly in Gregg v Scott [2005] UKHL 2. Mr Gregg’s GP negligently dismissed a lump under his arm as benign. The lump was non-Hodgkin’s lymphoma. By the time a correct diagnosis was made nine months later, the cancer had upstaged. The evidence showed that his prospects of ten-year disease-free survival had reduced from 42 per cent to 25 per cent because of the delay. The House of Lords held, by a majority of three to two, that this reduction in statistical prospects was not in itself a recoverable head of damage. A claimant cannot recover for the loss of a chance in a clinical negligence claim: they must show on the balance of probabilities that the delay caused an adverse outcome that would not otherwise have occurred.

This is a significant limitation, but it does not prevent claims where the causation picture is stronger. There are two routes through which causation can be established.

The first route is where the claimant’s prognosis at the time the diagnosis should have been made was above 50 per cent, and the delay has materially worsened it. Where a cancer was stage one and highly curable at the point of the missed referral but had advanced to stage three or four by the time it was diagnosed, a claimant can show that earlier diagnosis would more probably than not have led to a successful outcome. The balance of probabilities test is satisfied.

The second route is where the delay caused a distinct physical harm that is recoverable regardless of the survival question. Mr Gregg himself could recover for the fact that the upstaging of his cancer required him to undergo high-dose chemotherapy that he would not have needed with earlier diagnosis. The additional surgery, more aggressive treatment, worse side effects, or longer and harder recovery associated with a more advanced cancer are all recoverable heads of damage even where the underlying survival question cannot be resolved in the claimant’s favour. This second route makes a much broader category of cases viable than is sometimes appreciated.

Which Cancers Most Commonly Give Rise to Claims?

Colorectal cancer

Colorectal cancer is among the most commonly litigated cancers in clinical negligence. Symptoms including rectal bleeding, a change in bowel habit, unexplained weight loss, and iron deficiency anaemia are all covered by NG12 referral criteria. The most common failure is attribution of these symptoms to benign causes such as haemorrhoids or irritable bowel syndrome without adequate investigation. Five-year survival falls from approximately 90 per cent at stage one to approximately 10 per cent at stage four, making the causation case particularly strong in claims involving significant upstaging during a period of delayed diagnosis.

Lung cancer

Lung cancer is the most common cause of cancer death in the United Kingdom. A failure to arrange an urgent chest X-ray for a patient with persistent new cough, haemoptysis, or unexplained weight loss meeting the NG12 threshold, or a failure to act on an abnormal chest X-ray or CT finding, are the most common bases for a primary care claim. Radiological misdiagnosis, including a failure to identify a pulmonary nodule or mass that is objectively visible on the imaging, is a significant category of secondary care claim.

Breast cancer

Breast cancer is the most common cancer in women in England, and misdiagnosis claims arise from failures at every point in the pathway, including a failure to refer a breast lump meeting the NG12 criteria, an inadequate triple assessment in secondary care, and mammographic reporting errors. A failure to complete all three components of the triple assessment, clinical, radiological, and histological, where any one component has produced an abnormal finding, is a departure from the established standard that is very difficult to defend.

Prostate cancer

Prostate cancer misdiagnosis claims arise from a failure to refer where PSA results or relevant symptoms indicated a risk of cancer, and from a failure to act on a PSA trend showing a progressive rise over sequential measurements. The causation analysis in prostate cancer claims requires careful attention to the Gleason grade and clinical risk category of the tumour, since the natural history of a low-grade indolent tumour may not have been materially altered by a period of delay, whereas a high-grade aggressive tumour may have upstaged significantly during the same period.

Other cancers

Claims also arise in the context of ovarian cancer, where persistent bloating, abdominal pain, and urinary frequency should trigger a CA125 test and ultrasound under NG12; pancreatic cancer, where jaundice in an adult requires an urgent suspected cancer referral; skin cancer, including melanoma where a suspicious pigmented lesion was not referred or excised; and haematological malignancies including lymphoma, where persistent lymphadenopathy should be investigated with urgency.

What About Radiology and Pathology Errors?

Not all cancer misdiagnosis claims arise from a failure to refer. A significant category involves errors in the technical analysis of investigations.

A radiologist who fails to identify a lesion that is objectively present on the imaging, or who does not recommend appropriate follow-up of an indeterminate finding, may be liable for the delay in diagnosis that results. The case of Muller v King’s College Hospital NHS Foundation Trust [2017] EWHC 128 (QB) drew an important distinction in this context: where the question is whether a finding was correctly identified on a scan or slide, rather than which of several management options was the right clinical choice, the Bolam protection for differences of clinical opinion applies with less force. A defendant cannot easily argue that it is acceptable to miss a finding that any competent radiologist reviewing the imaging would have identified.

A pathologist who misclassifies a malignant biopsy specimen as benign is subject to the same analysis. Where independent expert review of the original slides shows that the malignant features were present and identifiable, the misclassification is difficult to defend.

What Compensation Is Available?

Compensation in a cancer misdiagnosis claim covers the additional harm caused by the delay, not the existence of the cancer itself.

General damages compensate for the additional pain, suffering, and loss of amenity caused by the delayed diagnosis. This includes the experience of more aggressive treatment, the additional side effects, the worsened prognosis, and the psychological impact of a diagnosis that is more serious than it would have been with earlier detection.

Special damages cover past financial losses caused by the delay, including lost earnings, the cost of private treatment that would not have been required at the earlier stage, the cost of care provided by family members, and other out-of-pocket expenses.

Future losses are relevant where the delay has permanently worsened the prognosis or resulted in longer-term disability, treatment needs, or loss of earning capacity. In cases where the delay has rendered the cancer incurable or has significantly shortened life expectancy, future losses including dependency claims under the Fatal Accidents Act 1976 can be very significant.

Claims following death can be brought by the estate under the Law Reform (Miscellaneous Provisions) Act 1934 for losses suffered before death, and by dependants under the Fatal Accidents Act 1976 for bereavement and financial dependency.

Time Limits

The standard three-year limitation period under the Limitation Act 1980 applies, running from the date of the negligent act or from the date of knowledge that the harm may have been caused by a clinical failure. Because the nature of a missed or delayed diagnosis is that the patient was told that their symptoms were benign or did not require investigation, the date of knowledge will often be significantly later than the date of the original consultation. Legal advice should be sought promptly once a possible connection between a clinical failure and harm is identified.

What to Do Next

If you believe that a cancer was missed or diagnosed later than it should have been, the following steps are involved in bringing a claim:

1. Seek specialist legal advice. A clinical negligence solicitor will assess the circumstances and advise on whether the clinical management appears to have fallen below the required standard.
2. Medical records are obtained. This includes all GP records, investigation results, imaging reports, pathology results, and specialist correspondence covering the relevant period.
3. Imaging and pathology material is preserved. Where radiology or pathology errors are suspected, the original imaging and histological slides are obtained for independent expert review.
4. Independent expert evidence is commissioned. A GP expert will address the primary care breach of duty question. An oncology expert will address the causation analysis: what stage the cancer was at the point of the missed referral, what it was at actual diagnosis, and what recoverable harm the difference represents.
5. A letter of claim is sent. Once the evidence supports the claim, this is sent to the defendant under the Pre-Action Protocol for the Resolution of Clinical Disputes.

Talk to Satchell Moran Solicitors

A delayed cancer diagnosis can alter the entire course of a patient’s treatment and prognosis. At Satchell Moran Solicitors, our specialist clinical negligence team handles cancer misdiagnosis claims across all major cancer types, including colorectal, lung, breast, prostate, ovarian, skin, and haematological malignancies, as well as radiology and pathology errors and screening programme failures. We act on a no win, no fee basis, and as a dual Lexcel accredited firm we are committed to the highest standards of client care throughout.

If you believe that a cancer diagnosis was delayed or missed as a result of clinical negligence, contact us today for an initial, confidential and no obligation conversation.